Skip to main content
OpenTrials
Completed

NCT Number: NCT01630252

PGL5001 Proof of Concept Study in Inflammatory Endometriosis

This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with concomitant DMPA administration for the treatment of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the parts A2 and B are double-blind.

The target population will be women of reproductive age and suffering from newly diagnosed peritoneal and/or ovarian endometriosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o.

Bialystok, 15-224, Poland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The Subject must provide written informed consent prior to initiation of any study related procedures.
  • The Subject must be an adult woman of reproductive age, aged from 18 and above.
  • The Subject must be a newly diagnosed patient suffering from peritoneal and/or ovarian endometriosis with at least 15% of the endometriotic lesions observed at the study diagnostic laparoscopy being red inflammatory lesions and with a proven histological diagnosis.
  • The Subject must consent to the scheduling of a second laparoscopy for surgical treatment at the study end.
  • The Subject must have a history of pelvic pain for at least 3 months prior to the screening visit.

Exclusion criteria

  • The Subject is over 40 years old and has a FSH serum level during Day 2-4 of her cycle ≥ 21.5 mIU/ml.
  • The Subject has a positive pregnancy test at baseline or is breast-feeding or planning a pregnancy during the course of the study.
  • The Subject is known for having a cause of chronic abdominal/pelvic pain other than endometriosis (e.g. inflammatory bowel disease, fibromyalgia, interstitial cystitis).
  • The Subject has a history of surgical treatment for endometriosis prior to the study diagnostic laparoscopy.
  • The Subject is requiring urgent surgical excision of endometriotic lesions at the time of first diagnostic laparoscopy.
  • The Subject has a history (in the past 12 months) of or a current medical treatment for endometriosis other than NSAID (e.g. GnRH agonist or antagonist, danazol, continuous oral combined oestroprogestogens).

Treatment and study plan

PGL5001

Drug

PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection

Placebo

Drug

PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection

Primary outcomes

  1. Change from baseline to end of treatment in the number and percentage of red lesions (and/or inflammatory lesions), based on total number of red and black lesions.

    Time frame: at week 8, week 20

Sponsors and collaborators

Lead sponsor

PregLem SA

Industry

Registry information

Official study title

A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.

Acronym: JADE

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jun 28, 2012
Registry last updated
Jun 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.